51726-83-1

Basic information

• Product Name: 4-OXO-1,4-DIHYDROBENZO[H]QUINOLINE-3-CARBOXYLIC ACID
• Synonyms: OTAVA-BB BB0107830116;SALOR-INT L149209-1EA;AURORA 17737;CHEMBRDG-BB 5871514;4-OXO-1,4-DIHYDROBENZO[H]QUINOLINE-3-CARBOXYLIC ACID;NSC 210902;OTAVA-BB 0107830116;4-oxo-1,4-dihydrobenzo[h]quinoline-3-carboxylic acid(SALTDATA: FREE)
• CAS NO: 51726-83-1
• Molecular Formula: C14H9NO3
• Molecular Weight: 239.23
• Mol File: 51726-83-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 458.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.437±0.06 g/cm3(Predicted)
• PKA: 5.52±0.20(Predicted)
• CAS DataBase Reference: 4-OXO-1,4-DIHYDROBENZO[H]QUINOLINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-OXO-1,4-DIHYDROBENZO[H]QUINOLINE-3-CARBOXYLIC ACID(51726-83-1)
• EPA Substance Registry System: 4-OXO-1,4-DIHYDROBENZO[H]QUINOLINE-3-CARBOXYLIC ACID(51726-83-1)

Safety Data

• Hazardous Substances Data: 51726-83-1(Hazardous Substances Data)

Usage

General Description

4-oxo-1,4-dihydrobenzo[h]quinoline-3-carboxylic acid is a chemical compound with potential pharmaceutical applications. It is a quinoline derivative with a carboxylic acid group, making it a potential drug candidate for various therapeutic uses. Quinolines have been studied for their antimalarial properties, and the presence of a carboxylic acid group suggests potential for targeting specific biological pathways. The compound’s structure also contains a keto group, which may contribute to its pharmacological activity. Further research is needed to fully understand the potential applications of this chemical in drug development and medical treatment.

Upstream product

• 131775-94-5 2-[(naphthalen-1-ylamino)methylidene]malonic acid diethyl ester 
• 134-32-7 1-amino-naphthalene 
• 71083-13-1 ethyl 4-oxo-1,4-dihydrobenzoquinoline-3-carboxylate 

Relevant articles and documents

Novel quinolone-3-carboxylic acid derivatives as anti-HIV-1 agents: design, synthesis, and biological activities

A new series of quinolone-3-carboxylic acids featuring different hydrophobic groups at N-1, C-2, C-7, and C-8 positions were synthesized and evaluated for their activity against single-cycle replicable HIV NL4-3 as inhibition rate of p24 expression in Hela cells cultures. Most of the synthesized compounds showed anti-HIV activity with no significant cytotoxicity at concentration of 100 μM. The most active compounds 4h, 4k, and 4j exhibited anti-HIV activity with an inhibition rate of 55, 71, and 84 %, respectively. A docking study using the crystallographic data available for PFV integrase including its complexes with Mg2+ and Raltegravir revealed that the active compounds could occupy same space near Raltegravir and interact with the Mg2+ ions in the active site. Thus, the anti-HIV activity of the synthesized compounds might involve a metal chelating mechanism. [InlineMediaObject not available: see fulltext.]

Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2

Due to the emerging role of protein kinase CK2 as a molecule that participates not only in the development of some cancers but also in viral infections and inflammatory failures, small organic inhibitors of CK2, besides application in scientific research, may have therapeutic significance. In this paper, we present a new class of CK2 inhibitors-3-carboxy-4(1H)-quinolones. This class of inhibitors has been selected via receptor-based virtual screening of the Otava compound library. It was revealed that the most active compounds, 5,6,8-trichloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (7) (IC 50 = 0.3 μM) and 4-oxo-1,4-dihydrobenzo[h]quinoline-3-carboxylic acid (9) (IC50 = 1 μM), are ATP competitive (Ki values are 0.06 and 0.28 μM, respectively). Evaluation of the inhibitors on seven protein kinases shows considerable selectivity toward CK2. According to theoretical calculations and experimental data, a structural model describing the key features of 3-carboxy-4(1H)-quinolones responsible for tight binding to CK2 active site has been developed.